EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 747 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA New Survey Highlights the Role of Clinical Practice Guidelines to Improve Care for Patients with Rare Cancers FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation MOST POPULAR 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... September 23, 2024 Cabozantinib Improves PFS in Patients with Previously Treated, Progressive Advanced Extrapancreatic... October 25, 2024 Creating a shared vision to detect cancer earlier October 15, 2020 ΠΟΝΟΣ March 8, 2019 Load more HOT NEWS As Use of Genomic Data Expands in Cancer Care, Patients Share... 10 Ways to Provide Support During Breast Cancer Awareness Month Happy Holidays from the OncoLink Team Estimate of the Global Economic Cost of the Most Prevalent Cancers...
